Merck (MRK) Misses Q4 EPS by 9c; misses on outlook

Merck (NYSE: MRK) reported Q4 EPS of $1.72, $0.09 worse than the analyst estimate of $1.81. Revenue for the quarter came in at $15.6 billion versus the consensus estimate of $15.47 billion.

GUIDANCE:

Merck sees FY2025 EPS of $8.88-$9.03, versus the consensus of $9.21. Merck sees FY2025 revenue of $64.1-65.6 billion, versus the consensus of $67.36 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
• Altimmune, Inc. (ALT) Tops Q2 EPS by 3c
• Local Bounti Corporation (LOCL) Misses Q2 EPS by 18c